Nanosphere to Present Data on the Verigene(R) System at the 2013 Interscience Conference on Antimicrobial Agents and

Nanosphere to Present Data on the Verigene(R) System at the 2013 Interscience 
Conference on Antimicrobial Agents and Chemotherapy
(ICAAC) 
NORTHBROOK, IL -- (Marketwired) -- 08/22/13 --  Nanosphere, Inc.
(NASDAQ: NSPH), a company enhancing medicine through targeted
molecular diagnostics, today announced that it will present data from
eight studies at the 53rd Interscience Conference on Antimicrobial
Agents and Chemotherapy (ICAAC), September 10-13, 2013, in Denver,
CO. Six studies will illustrate the accuracy and reliability of
Nanosphere's Verigene(R) System in detecting bloodstream infections.
A seventh study compares the accuracy of the Verigene System versus
the BioFire FilmArray for rapid identification of gram-positive
bacteria in blood cultures; and an eighth compares the accuracy of
the Verigene System with Meridian BioScience's Illumigene and
Quidel's AmpliVue for rapid identification of C. difficile in stool.  
"We are pleased with the growing body of clinical evidence that
demonstrates the sensitivity and specificity of the Verigene System
in rapidly and accurately detecting infectious pathogens and drug
resistance markers," said Michael McGarrity, Nanosphere's president
and chief executive officer. "Early and accurate diagnosis,
particularly for critical bloodstream and gastrointestinal
infections, is vital to healthcare providers for determining the most
appropriate course of treatment for their patients." 
Nanosphere data to be presented at ICAAC: 
1. Poster D-106: "Nanosphere Verigene v BioFire FilmArray for Rapid
ID of Gram-Positive Cocci in Blood Cultures," Dr. C.J. Sailey et al.;
Arkansas Children's Hospital and the University of Arkansas, Ark.
[Tuesday, September 10th, 12 - 1 pm]  
2. Poster D-107: "Clinical Performance Characteristics of the
Nanosphere Verigene Gram Positive Blood Culture Test," T. Wakefield
et al.; The Johns Hopkins Clinical Microbiology Laboratory and the
Department of Pathology of the Johns Hopkins University School of
Medicine, Md. [Tuesday, September 10th, 12 - 1 pm]  
3. Poster D-108: "Evaluation of the Verigene BC-GP Test for
Identification of Gram-Positive Organisms from Positive Versatrek
Blood Culture (BC) bottles," Dr. E. L. Palavecino et al.; Wake Forest
Baptist Medical Center, N.C. [Tuesday, September 10th, 12 - 1 pm]  
4. Poster D-109: "Impact of Rapid Molecular Identification of
Gram-Positive Cocci and Resistance Determinants in Positive Blood
Cultures on Targeted Antibiotic Therapy of Bacteremia Due to
Gram-Positive Cocci," Dr. R.M. Martinez et al.; University of
Washington, Wash. [Tuesday, September 10th, 12 - 1 pm]  
5. Poster D-110: "Evaluation of Verigene Gram-Positive and
Gram-Negative Blood Culture Assays Performance for Bacteremic
Patients," Ph. M. Dodemont et al.; Hopital Erasme, Brussels.
[Tuesday, September 10th, 12 - 1 pm]  
6. Poster D-111: "Evaluation of Microarray Based Rapid Diagnostic
Test for Direct Identification of Gram-Negative Bacteria and
Resistance Genes From Positive Blood Cultures," Dr. M. Tojo et al.;
Disease Control and Prevention Center, Tokyo, Japan. [Tuesday,
September 10th, 12 - 1 pm]  
7. Poster D-112: "Evaluation of a Microarray-Based Sample-to-Result
Assay for the Rapid Detection of Gram-Negative Bacteria and
Antibiotic Resistance Markers Directly from Positive Blood Culture
Bottles," Dr. R. A. Winegar et al.; MRIGlobal, Fla. [Tuesday,
September 10th, 12 - 1 pm]  
8. Poster C-1147a: "Correlation of Illumigene, Verigene, and AmpliVue
for Rapid Identification of C. difficile in Stool," Dr. C.J. Sailey
et al.; Arkansas Children's Hospital and the University of Arkansas,
Ark. [Thursday, September 12th, 11am - 1 pm] 
About the Verigene(R) System  
The Verigene(R) System uses core proprietary gold nanoparticle
chemistry to offer highly sensitive, highly specific molecular
diagnostic results through low-cost multiplexing. The Verigene System
rapidly and accurately detects infectious pathogens and drug
resistance markers by mapping the genome of a particular bacterium.
Currently, Verigene assays target infections of the bloodstream,
respiratory tract and gastrointestinal tract. The System also offers
additional capabilities in cancer, cardiovascular disease and
autoimmune disease. The information gathered from Verigene enables
clinicians to identify diseases earlier and make informed patient
treatment decisions more quickly, which may result in improved
patient outcomes, reduced costs, optimized antibiotic therapy,
reduced spread of antibiotic resistance and saved lives. 
About Nanosphere, Inc.  
Nanosphere is enhancing medicine through targeted molecular
diagnostics that result in earlier disease detection, and enable
optimal patient treatment and improved healthcare economics. The
Company's versatile technology platform, the Verigene(R) System,
allows clinicians to rapidly identify the most complex, costly and
deadly infectious diseases through simple-to-use multiplexed
diagnostic testing. The combination of this innovative technology and
Nanosphere's customer-driven solutions keeps commitment to the
patient at the forefront of its business. Nanosphere is based in
Northbrook, IL. Additional information is available at
http://www.nanosphere.us. 
Contacts 
Investors:
Roger Moody
Chief Financial Officer
847-400-9021
rmoody@nanosphere.us 
Media:
Lindsey Saxon
Director of Communications
847-400-9173
lsaxon@nanosphere.us 
Geoff Curtis
Edelman
312-233-1253
geoff.curtis@edelman.com 
 
 
Press spacebar to pause and continue. Press esc to stop.